1. GOODMAN, L, WINTROBE, M. M., DAMESHEK, W., GOODMAN, M. J., GILMAN, A., and MCLENNAN, M. T.; Nitrogen mustard therapy; use of methylbis (B -chloroethyh) amine hydrochioride and tris(B-chloroethyl)amine hydrochioride for Hodgkin’s disease, lymphosarcoma, leukemia and certain allied and miscellaneous disorders. JAMA 132; 126, 1946.
2. JACOBSON, L. O., SPURR, C.L., GUZMAN BARRON, E. S., SMITH, T., LUSHBAUGH, C., and DICK, G. F.: Nitrogen mustard therapy; studies on the effect of methyl-bis(Bis-chloroethyl)-amine hydrochioride on neoplastic diseases and allied lisorders of the hemopoietic system. 1946.
3. WINTROBE, M. M., MCLENNAN, M. T., and HUGULEY, C. M., Jr.; Clinical experiences with nitrogen mustard therapy. In; Approaches to Tumor Chemotherapy, p. 347. Washington, D. C., Am. Assoe. Advancement Science, 1947.
4. KARNOFSKY, D. A., BURCHENAL, J. H., ORMSBEE, R. A., CORNMAN, I., and RHOADS, C. P.; Experimental observations on the use of the nitrogen mustards in the treatment of neoplastic diseases. In; Approaches to Tumor Chemotherapy, p. 293. Washington, D. C., Am. Assoe. Advancement Science, 1947.
5. KARNOFSKY, D. A., BURCHENAL, J. H., ARMISTEAD, G. C., Jr., SOUTHAM, C. M., BERNSTEIN, J. L., CRAVER, L. F., and RHOADS, C. P.: Triethylene melamine in the treatment of neoplastic disease; a compound with introgen-mustard-like activity suitable for oral and intravenous use. A.M.A. Arch. Int. Med. 87; 477, 1951.